


Remarks

Applicants' Attorney hereby states that the change made in the sequence listing, does not include new matter. Applicants' undersigned attorney has amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application. Applicants have also amended the specification to accurately reflect that the correct sequence identification numbers within the specification now correspond to the sequence identification numbers contained in the Sequence Listing submitted herewith.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same. It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: Nov. 21, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version of Amendment With Markings to Show Changes Made

In the Specification:

The paragraph on page 31, lines 23-29:

The annealing mix was prepared by mixing 1 μ g of MAP4 mRNA and biotinylated *Not* I oligo(dT)₂₅ primer ((Biotin)₄-GACTAGTTCTAGAT CGCGAGCGG CCGCCCTTTT TTTTTTTTTTTT TTTTTTTT (SEQ ID NO:1); see WO 98/51699) in the desired molar ratio of oligo (dT)/mRNA of 0:1, 1:1 or 15:1 in thin-walled PCR tubes and bringing the volume up to 10 μ l with water. If several tubes are identical, they may be made in one batch and aliquotted accordingly. The annealing mix was kept on ice.

The paragraph on page 37, lines 10-17:

All conditions and parameters described above in Examples 2, 3 (RNase I) and 4 were followed, except for the following: 4 reactions of 10 μ g of human fibroblast cytoplasmic mRNA were used per reaction (see WO 98/45311); the biotinylated primer-adapter (Biotin)₄-GACTAGTTCTAGATCGCGAGCGGCCGCC(T)₂₅ (SEQ ID NO:1) was used at a 1:1 primer/mRNA molar ratio; TS II RT was used at 50°C; and SS II RT was used at 45°C. Table 8 below summarizes the first strand cDNA and eIF-4E capture results.

RECEIVED

NOV 2 6 2002

TECH CENTER 1600/2900